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Abstract. Arsenic trioxide (ATO) has demonstrated anti-
cancer activity in different malignancies, especially acute 
promyelocytic leukemia, with a wide array of putative 
mechanisms. In this study, we aimed to elucidate the activity 
and mechanisms of ATO in small cell lung cancer (SCLC). 
A panel of SCLC cell lines (H841, DMS79, H526, H69 and 
H187) was employed to demonstrate the activity of ATO. 
Cell viability, apoptosis and mitochondrial membrane depo-
larization were assessed. Western blotting was performed to 
determine the alteration of pro-apoptotic and anti-apoptotic 
mediators. Reactive oxygen species (ROS) (hydrogen peroxide 
and superoxide) and intracellular glutathione (GSH) were 
measured. Antioxidants, N-acetyl-L-cysteine (NAC) and 
butylated hydroxyanisole (BHA), were applied to restore GSH 
content and reduce production of ROS. All SCLC cell lines 
were relatively sensitive to ATO with IC50 values below 10 µM. 
ATO induced cell death mainly through apoptosis in H841 
cells in a dose-dependent manner. Hydrogen peroxide was the 
major ROS in SCLC cells induced by ATO. Along with GSH 
depletion and Bcl-2 downregulation, mitochondrial membrane 
permeabilization was enhanced, followed by release of AIF 
and SMAC from mitochondria to initiate different cell death 
pathways. NAC reversed cell death and molecular changes 
induced by ATO via restoring GSH and reducing ROS content. 
BHA inhibited hydrogen peroxide production completely and 
partially restored GSH content accounting for partial reversal 
of cell inhibition and mitochondrial dysfunction. Nonetheless, 
ATO reduced both reduced and oxidized form of thioredoxin 1 
(Trx1) with no effect on Trx1 redox potential. ATO led to cell 
death in SCLC mainly through mitochondrial dysfunction, 
resulting from altered cellular redox homeostasis, namely, 
hydrogen peroxide generation, GSH depletion and Trx1 down-
regulation.
Introduction
SCLC, accounting for 15-20% of newly diagnosed lung 
cancer, is an extremely aggressive malignancy with early 
metastasis and poor prognosis. Despite a prompt response to 
chemotherapy, relapses occur in the majority of patients with 
SCLC. Therefore the development of an alternative therapy 
against SCLC becomes imperative (1).
ATO has been proven to be an effective therapeutic agent 
in acute promyelocytic leukemia (APL) with high complete 
remission rate and prolonged survival (2,3). ATO can induce 
apoptosis through PML-RARα-independent pathways in APL 
or other cancer cells via p53 activation (4,5), Bcl-2 down-
regulation (6,7), mitochondrial membrane depolarization and 
cytochrome c release (8-10), depletion of intracellular reduced 
glutathione (GSH) content and elevation of reactive oxygen 
species (11,12). More recently, the application of ATO in lung 
cancer treatment has been explored in preclinical models, 
mainly in non-small cell lung cancer (NSCLC). ATO induces 
growth inhibition and apoptosis in NSCLC cells through 
G2/M cell cycle arrest (13,14), Bcl-2 downregulation and 
GSH depletion (15). Recently, downregulation of thymidylate 
synthase and E2F1 were observed in lung adenocarcinoma 
(16,17) and mesothelioma (18). Synergistic effects have been 
observed when combining ATO with cisplatin (19), buthionine 
sulfoximine (BSO) (15), suberoylanilide hydroxamic acid (20), 
and sulindac (21). The effect of ATO in SCLC is less reported. 
In a panel of lung cancer cell lines, ATO is highly cytotoxic 
to SCLC preferentially mediated through necrosis rather than 
apoptosis (22).
Biologically, ATO is known to bind to proteins with 
sulfhydryl (-SH) groups (23). It targets GSH which is a thiol 
molecule involved in detoxification of arsenicals (11,24). 
Evidently, loss of GSH and its cytotoxic effect is not directly 
caused by damage of GSH-related enzymes (glutathione 
peroxidase, glutathione reductase and glutathione transferase)
(25). Nonetheless, thioredoxin (Trx) system serves as a key 
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antioxidant target of ATO in breast cancer cells (26). Trx 
system, composed of thioredoxin reductase (TrxR), Trx and 
NADPH, plays an important role in maintaining somatic redox 
homeostasis. Moreover, TrxR and Trx are overexpressed in 
many cancers (27-29), which take part in redox regulation of 
transcription factors (30). Therefore, Trx system has become a 
new target in cancer therapy (31).
In the present study, we aimed to elucidate the mechanisms 
of ATO in SCLC using a cell line model, which may provide 
a scientific base for future application of ATO in treatment of 
SCLC.
Materials and methods
Chemicals and reagents. ATO, N-acetyl-L-cystine (NAC), 
buthionine sulphoximine (BSO) and butylated hydroxy-
anisole (BHA) were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Apoptosis inducing factor (AIF), Bcl-2, cleaved 
caspase-3, cytochrome c, PARP, SMAC, thioredoxin and XIAP 
antibodies were purchased from Cell Signaling Technology 
(Danvers, MA, USA).
Cell lines and culture. Five SCLC cell lines (H187, DMS79, 
H526, H69 and H841) were obtained from the American Type 
Culture Collection (Manassas, VA, USA). H187, DMS79, H526 
and H69 cells were cultured in RPMI-1640 medium (Gibco®, 
Life Technologies, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum (FBS, Gibco), while H841 cells were 
grown in HETIS medium supplemented with 5% FBS. Cells 
were incubated in 37˚C with a humidified atmosphere of 
5% CO2.
Cell proliferation assay. The cytotoxicity of ATO in SCLC 
cell lines was measured using 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide (MTT) assay (ATCC) as 
previously performed (32).
Annexin V-phycoerythrin (PE)/7-aminoactinomycin D 
(AAD) staining. Apoptosis was determined by PE-conjugated 
Annexin V/7-AAD kit (BD Biosciences, CA, USA). Briefly, 
treated cells were collected, washed and re-suspended in 
binding buffer. Cells were stained for 15 min at room tempera-
ture with PE-Annexin V (Ex/Em = 488/578 nm)/7-AAD 
(Ex/Em = 546/647 nm), then read-out by Cytomics FC 500 
analyzer with FL2/FL4 channels (Beckman Coulter, CA, 
USA). The cell populations in PE+/7-AAD- and PE+/7-AAD+ 
quadrants were calculated.
Measurement of mitochondrial membrane depolarization 
(MMD). Briefly, cells after treatment were collected, washed, 
and stained with JC-1 (5 µg/ml) at 37˚C for 15 min before 
reading with FL1/FL2 channels of Cytomics FC 500 analyzer.
Detection of glutathione (GSH) and reactive oxygen species 
(ROS). Cellular GSH level was measured by using 5-chloro-
methylfluorescein diacetate (CMFDA, Ex/Em = 522/595 nm, 
Invitrogen, CA, USA) fluorescence as described previously 
(33). After treatment, cells were washed and incubated for 
30 min at 37˚C with 5 µM CMFDA in FBS-free medium, 
followed by incubation for 40 min at 37˚C with complete 
medium. CMF fluorescence intensity was determined using a 
Cytomics FC500 flow cytometer. Hydrogen peroxide (H2O2) 
and superoxide were measured by 2',7'-dichlorodihydro-
fluorescein diacetate (H2DCFDA, Ex/Em = 500/520 nm) and 
dihydroethidium (DHE, Ex/Em = 518⁄605 nm) (Invitrogen) 
staining, respectively. Treated cells were washed and incubated 
for 20 min at 37˚C with 1 µM of H2DCFDA or 1 µM DHE in 
FBS-free medium following flow cytometry.
Immunofluorescence. Oxidative DNA damage was assessed 
using 8-hydroxy-2-deoxyguanosine (8-OHdG) immuno-
fluorescence. Cells were seeded on slides before treatment. 
Slides were washed and blocked for 60 min with 10% normal 
goat serum in PBS, followed by incubation at 4˚C over-
night with monoclonal anti-8-OHdG antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA). The slides were 
then incubated for 2 h with FITC-conjugated goat anti-mouse 
IgG (Santa Cruz Biotechnology, Ex/Em = 500/520 nm), cover-
slipped with UltraCruz™ Mounting Medium (Santa Cruz 
Biotechnology) and observed with Eclipse E-800 (Nikon, 
Tokyo, Japan). DAPI (Santa Cruz Biotechnology) staining was 
used to visualize the nucleus.
Western blotting. Total protein was extracted with RIPA buffer 
(PBS, 1% Nonidet-P-40, 0.1% deoxycholate, 0.1% sodium 
dodecyl sulfate) containing protease inhibitors. Nuclear protein 
and mitochondrial protein were collected with NE-PER 
Nuclear and Cytoplasmic Extraction kit and Mitochondria 
Isolation kit respectively (Pierce Biotech, Rockford, IL, USA) as 
described by the manufacturer. Proteins (40 µg) were separated 
in sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE), transferred to nitrocellulose membrane 
(GE Healthcare, Buckinghamshire, UK), immunoblotted with 
corresponding primary and secondary antibodies, and detected 
using ECL detection kit (GE Healthcare). Image analysis was 
carried out with ImageJ (Research Services Branch, National 
Institute of Mental Health, Bethesda, MD, USA).
DNA fragmentation assay. Cellular DNA was extracted with 
standard DNA phenol/chloroform extraction method (34). 
DNA (0.1 µg/sample) was separated in 1.5% agarose gel and 
bands were visualized on a UV transilluminator at 302 nm.
Redox western blot analysis. Redox forms of Trx1 were 
separated as previously described (26,35). Trx1 was carboxy-
methylated in guanidine-Tris solution (6 M guanidine-HCl, 
50 mM Tris, 1 mM EDTA, 30 mM iodoacetic acid) at pH 7.5. 
After incubation at 37˚C for 30 min, proteins were desalted 
and concentrated using centrifugal filter device (Millipore, 
Billerica, MA, USA). Proteins were separated with native gel 
and western blotting was performed. Redox potential was 
calculated with Nernst equation: Eh, Trx1 = 240 mV + 30 x ln 
(ratio of Trx1Ox and Trx1Red) (36).
Statistical analysis. Data were presented as mean ± standard 
deviation (SD), with between-group differences analyzed by 
two-tailed Student's t-test. A p-value <0.05 was considered 
statistically significant. Linear regression was used to calcu-
late IC50 values. All statistical analyses were performed using 
Prism 5 (GraphPad Software, La Jolla, CA, USA).
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Results
Cell growth inhibition and apoptosis induced by ATO. 
Five SCLC cell lines were incubated for 48 h with different 
concentrations of ATO. Cell proliferation was suppressed 
in a dose-dependent manner with IC50 values in clinically 
reachable levels (Fig. 1A). H841 cell line was chosen due to 
its adherent property for apoptotic assay. ATO induced dose-
dependent apoptosis (Fig. 1B) in H841 cells accompanied by 
increased cleaved caspase-3 and PARP (Fig. 1C).
ATO-induced MMD, GSH depletion and ROS elevation. ATO 
prompted a dose-dependent shift from red to green fluores-
cence that indicated MMD in H841 cells (Fig. 2A). This was 
associated with downregulation of Bcl-2 and XIAP as well as 
release of AIF and SMAC to cytosol (Fig. 2B). Low concentra-
tion of ATO (2.5 µM) reduced 60% of GSH content (Fig. 2C) 
and increased H2O2 by >1.5-fold compared with control H841 
cells (30500±6150 vs 13522±3146) (Fig. 2D). Nonetheless, 
superoxide content remained unchanged except at the highest 
concentration (10 µM) of ATO treatment (Fig. 2D).
ATO induced oxidative DNA damage and fragmentation. 
Treatment with ATO (5 µM) resulted in stronger FITC fluo-
rescence (green) than in the control group, in keeping with 
increased 8-OHdG content in H841 cells upon exposure to ATO 
(Fig. 3A). This is associated with appearance of lower molecular 
weight DNA fragments with ATO treatment (Fig. 3B).
Changes in MAPKs expression during ATO treatment. Elevation 
of p-Erk1/2 was detected after 30 min of ATO treatment and it 
was sustained for ≥48 h (Fig. 4A) while p-P38 and p-JNK were 
unaltered (data not shown). Nonetheless, application of specific 
p-Erk1/2 inhibitor (PD98059) (20 µM) decreased p-Erk1/2 
Figure 1. Cytotoxicity of ATO in SCLC cell lines. (A) Dose-dependent growth inhibition in five SCLC cell lines (H187, H526, H69, DMS79 and H841) with 
ATO treatment. (B) Dose-dependent increase in apoptotic cell death, (C) cleaved caspase-3 and cleaved PARP with ATO treatment in H841 cells. Statistical 
significance (*p<0.05; **p<0.01 and ***p<0.001) indicates comparison with control.
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Figure 2. Effect of ATO on mitochondrial membrane permeability, apoptotic mediators or inhibitors as well as GSH depletion and H2O2 accumulation. 
(A) Increased mitochondrial membrane depolarization (MMD) with ATO treatment as indicated by JC-1 staining. J1 represents the proportion of the cells with 
MMD. (B) Downregulation of apoptotic inhibitors (Bcl-2 and XIAP) with ATO treatment, associated with translocation of AIF and Smac from mitochondria 
to nucleus and cytosol respectively.
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Figure 2. Continued. (C) ATO depleted GSH at 2.5 µM, with similar degree of suppression up to 10 µM. M1 represents the GSH content. (D) ATO significantly 
increased H2O2 at 2.5-10 µM, while superoxide was significantly raised only at the highest concentration of ATO at 10 µM. Statistical significance (*p<0.05; 
**p<0.01 and ***p<0.001) indicates comparison with control.
Figure 3. ATO caused DNA damage in H841 cell line. (A) The degree of 
oxidative DNA damage, as indicated by FITC-8-OHdG staining, was evident 
with ATO treatment (5 µM) compared with control. (B) DNA fragmentation 
was noted with ATO treatment at different concentrations.
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expression induced by ATO (Fig. 4B) but did not reverse 
ATO-induced cell death and MMD (Fig. 4C).
Effects of antioxidants on cell death induced by ATO. NAC, 
a cysteine donor in GSH synthesis, was used to determine the 
role of GSH and ROS in ATO-induced cell death in H841 
cells. NAC (10 mM) was shown to effectively restore GSH 
content and reduce H2O2 after ATO exposure (Fig. 5A). This 
was associated with reversal of apoptotic cell death (39.6±5.3 
vs. 5.3±1.2% for ATO vs ATO + NAC) and MMD (34.5±4.5 
vs. 5.6±0.4% for ATO vs. ATO + NAC) (Fig. 5B). In addition, 
NAC reversed the alterations in apoptosis-related proteins 
induced by ATO (Bcl-2, XIAP, cleaved caspase-3 and cleaved 
PARP) (Fig. 5C). On the other hand, a different antioxidant 
BHA suppressed H2O2 induced by ATO but failed to restore 
GSH content. Consequently, BHA only partially reversed 
apoptosis and MMD induced by ATO (Fig. 5D).
BSO potentiated cytotoxic effect of ATO by further disturbing 
the redox status. BSO, an inhibitor of γ-glutamylcysteine 
synthetase, was used as a GSH inhibitor. BSO potentiated the 
cytotoxic effect of ATO in H841 cells, as shown by increased 
apoptotic death (PE+ by flow cytometry in 17 vs. 44%: ATO 
vs. ATO + BSO), enhanced MMD (17 vs. 42%: ATO vs. ATO 
+ BSO), increased cleavage of caspase-3 and downregulated 
XIAP (Fig. 6A). Nonetheless, administration of 10 mM NAC 
Figure 4. Upregulation of p-Erk1/2 with ATO in H841 cells had no cytotoxic effect. (A) Dose- and time-dependent induction of p-Erk1/2 upon ATO treatment. 
(B) PD-98059 (20 µM) (Erk inhibitor) effectively suppressed ATO-induced pErk1/2, without alleviating effect on mitochondrial membrane depolarization and 
apoptosis initiated by ATO. Statistical significance (*p<0.05; **p<0.01 and ***p<0.001; ns, not significant) indicates comparison with control.
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only partially rescued the H841 cells from apoptosis and 
MMD (Fig. 6A). Interestingly, BSO caused more accumula-
tion of H2O2 than further depletion of GSH when combined 
with ATO (Fig. 6B), resulting in increased oxidative DNA 
damage (8-OHdG-FITC signal) in BSO/ATO group compared 
with either ATO or BSO alone (Fig. 6C).
Figure 5. Role of oxidative stress in ATO-mediated apoptosis in H841 cell line. Addition of NAC (10 mM) to ATO (5 µM) resulted in (A) complete reversal 
of ATO-induced alterations in GSH and H2O2 content, (B) protection from mitochondrial membrane depolarization and apoptotic cell death induced by ATO, 
and (C) normalization of downregulated anti-apoptotic molecules (Bcl-2 and XIAP) and upregulated apoptotic markers (cleaved caspase-3 and cleaved PARP) 
due to ATO.
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Figure 5. Continued. However, (D) BHA (0.1 mM) could suppress ATO-induced H2O2 accumulation without restoration of GSH, leading to only partial 
alleviation of mitochondrial membrane depolarization and apoptosis. Statistical significance (*p<0.05; **p<0.01 and ***p<0.001; ns, not significant) indicates 
comparison with control.
Figure 6. Effect of BSO on cytotoxicity of ATO in H841 cells. (A) BSO potentiated the mitochondrial membrane depolarization and apoptotic cell death due to 
ATO, accompanied by increased cleaved caspase-3 and decreased XIAP, which could only be partially reversed by NAC. (B) BSO increased H2O2 dramatically 
rather than depleting GSH further when combined with ATO, which could not be restored by NAC. Statistical significance (*p<0.05; **p<0.01 and ***p<0.001; 
ns, not significant) indicates comparison with control.
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Trx1 is one of the important components of Trx redox 
system responsible for maintaining redox equilibrium in 
mammalian cells. ATO reduced total Trx1 protein expression 
in H841 cells, which could be further downregulated by BSO 
but was reversed by NAC (Fig. 6D). Based on Trx redox western 
blot analysis, both oxidized and reduced forms of Trx1 were 
downregulated by ATO, nevertheless, redox potential (Eh) 
remained the same in different treatment groups (Fig. 6E).
Discussion
In the past decade, ATO has been used as a highly effec-
tive anticancer therapy in leukemia (particularly APL) with 
or without all-trans retinoic acid and achieving high rate of 
complete remission (2,3). Nonetheless, it has been increas-
ingly reported to exert cytotoxic effect in other forms of 
haematological malignancies and solid cancers such as breast 
(37), ovarian (38), cervical (39), and lung (20) cancers. The 
mechanisms and pathways involved are highly diverse and cell 
type-specific, though knowledge is scarce in SCLC.
In this study, a panel of five SCLC cell lines was tested for 
the effect of ATO on cellular proliferation, with IC50 values in 
clinical achievable concentrations (3).
Caspase-dependent apoptosis is classified into intrinsic 
(mitochondria-mediated) and extrinsic (death receptor-medi-
ated) pathways (40). Both mechanisms converge to activate the 
Figure 6. Continued. (C) BSO enhanced oxidative DNA damage when combined with ATO, as indicated by 8-OHdG-FITC staining. (D) ATO reduced Trx1 
protein expression, which could be potentiated by BSO and reversed by NAC. (E) Despite reduction of both reduced and oxidized form of Trx1 by ATO 
(enhanced by addition of BSO), Trx1 redox potential was unaffected. Statistical significance (*p<0.05; **p<0.01 and ***p<0.001; ns, not significant) indicates 
comparison with control.
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apoptotic executioner caspase-3 and -7, which consequently 
cleave polyADP-ribose polymerase (PARP) that impairs DNA 
repair. Classically, cleaved caspase-3 and cleaved PARP are 
widely adopted apoptotic markers. In this study, both markers 
were elevated after ATO treatment in H841 cells, indicating 
cell death via the caspase-dependent pathway (41).
AIF is one of the main mediators in cell death, which 
is liberated from mitochondria and translocated to nucleus 
resulting in DNA damage. It has been suggested that nuclear 
translocation of AIF accompanied by activation of receptor 
interacting protein 1 (RIP1) are markers of necroptosis (42). 
Nonetheless, the binding of AIF with DNA provokes caspase-
independent chromatin condensation and DNA fragmentation 
(43-46). In our H841 cell line model, apart from triggering 
MMD accompanied by AIF release and nuclear transloca-
tion, ATO treatment also increased RIP1 expression (data not 
shown). Taken together, cell death initiated by ATO in H841 
cells could be mediated through both caspase-dependent 
apoptosis and AIF-induced apoptosis or necroptosis.
On the other hand, MMD is associated with mitochondrial 
release of another apoptosis mediator SMAC, in which cyto-
solic SMAC can inhibit apoptosis inhibitor protein (XIAP) 
leading to subsequent release of caspases that initiate apoptosis 
(40). Our finding of SMAC release and XIAP downregula-
tion during treatment with ATO in H841 cells suggests the 
possibility of caspase-3 activation via SMAC release/XIAP 
inhibition rather than cytochrome c release/caspase-9 activa-
tion. This is in keeping with previously reported mechanism 
of caspase-dependent apoptosis via SMAC/XIAP/caspase 
activation in other cancer cell line models with ATO treatment 
(47,48).
GSH depletion and H2O2 accumulation with ATO treatment 
in H841 cells detected in this study are in keeping with previous 
reports (11,49-52). Nonetheless, the type and amount of ROS 
needed to initiate cell death by ATO are still controversial, 
which can vary with different cell lines and dose of ATO (53). 
Indeed, the role of ROS in causing cell death induced by ATO 
was uncertain in other studies (54,55). Based on our findings 
in H841 SCLC model, oxidative stress with ATO treatment 
was due to both H2O2 production and GSH depletion, in which 
NAC (a GSH precursor) (56) could reverse these alterations 
resulting in restoration of mitochondrial membrane poten-
tial. In leukemia cell line U973, intracellular GSH depletion 
could trigger Bax translocation to mitochondria and provoke 
membrane permeabilization resulting in apoptosis (57). In 
H841 cell line, we demonstrated downregulation of Bcl-2 upon 
ATO treatment, abrogating the protection on mitochondria. 
The mechanism of ATO-induced Bcl-2 downregulation has 
not been clearly elucidated. Nonetheless Bcl-2 has manifested 
an antioxidant-like effect in response to either oxidative stress 
or GSH depletion (58,59). Reversal of ATO-induced Bcl-2 
downregulation with NAC in our experiments has suggested 
the mechanistic role of oxidative stress and GSH depletion.
BHA is an effective scavenger of free radicals widely used 
in food industry. It has been shown to be effective in scav-
enging H2O2 to rescue cells from the DNA damage (60-63). In 
our study, adding BHA with ATO in H841 cells was capable 
of reducing H2O2 without effective restoration of GSH content 
compared with ATO alone, resulting in partial reversal of 
cell inhibition and apoptosis induced by ATO. It is possible 
that depletion of GSH with ATO treatment is not only due to 
consumption by H2O2 mediated via glutathione peroxidase 
(GPx) (64) but also direct consumption by ATO (65). In addi-
tion, oxidative DNA damage was more pronounced in ATO 
treatment with BSO compared with ATO alone, associated 
with significant GSH depletion due to increased H2O2 as previ-
ously reported (66,67). Taken together, GSH depletion plays 
a more important role in ATO-induced cell death in SCLC, 
similar to previous findings in NSCLC (66).
Thioredoxin system was reported to be an important target 
of ATO in some cancers (26,68). In H841 cell line model, 
ATO downregulated both reduced and oxidative form of 
Trx1 without affecting redox status. This is discrepant from 
previous report, which indicated that ATO could inhibit 
thioredoxin reductase and consequently decrease the reduced 
form of Trx1 (68). Although the activity or expression of thio-
redoxin reductase has not been measured, our findings suggest 
that ATO targets the total Trx1 rather than just the reduced 
form in H841 cells.
MAPKs are potential ROS response factors, nonetheless, 
p-JNK and p-p38 were not involved in ATO-induced cell 
death in our H841 cell line model (data not shown), which 
is different from other cancer models (69-71). Although 
upregulated p-Erk1/2 was detected after ATO treatment in 
H841 cells, specific Erk inhibitor PD98059 failed to revert the 
effects induced by ATO on MMD and cell death. It suggests 
that p-Erk1/2 is not an effective mediator leading to cell death 
induced by ATO in SCLC, which may serve in other biological 
actions (72,73).
In conclusion, the mechanisms of cell death induced by 
ATO in SCLC are mainly dependent on altered redox homeo-
stasis that comprises GSH depletion, H2O2 accumulation 
and mitochondrial depolarization. Both caspase-dependent 
pathway mediated via Bcl-2/SMAC/XIAP/Caspase-3 and 
caspase-independent pathway mediated via AIF would take 
part in causing apoptosis and necroptosis in SCLC.
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